Roche's approach to buying Illumina may have cost the Swiss drug development and diagnostic firm a chance at the San Diego-based next-generation sequencing firm, Illumina President and CEO Jay Flatley tells Bloomberg.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: the Human Silencing Hub protein complex, and more.
Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.
The Kansas City Star examines issues surrounding newborn genome sequencing.
Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.